|AHFS/Drugs.com||International Drug Names|
|Biological half-life||1.5 h|
|Excretion||Renal and fecal|
|Chemical and physical data|
|Molar mass||283.112 g/mol|
|3D model (JSmol)|
|(what is this?)|
Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.
In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva. The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".
- "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
- NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006[dead link]
- "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.